Preventing Hospital Readmissions in Heart Failure: Results and Successes
Quality ImprovementPreventing Hospital Readmissions in Heart Failure with Quality-Focused Learning
0.5 AMA PRA Category 1 Credit(s) ™ 0.5 ACPE
January 23, 2020
The accreditation for this activity has expired.
Primary Audience:
Cardiologists, emergency medicine physicians, internists, NPs, PAs, pharmacists
Relevant Terms:
Heart failure
Stuart Russell, MD
Professor of Medicine
Regional Director of Heart Failure
Duke University School of Medicine
Durham, North Carolina
Stuart Russell, MD, is a Professor of Medicine at Duke University School of Medicine and the Regional Director of Heart Failure. He went to medical school at the University of Washington, did his training at Johns Hopkins (Internal Medicine), Duke (Cardiology), and UCLA (Heart transplantation). He returned to Duke 2 years ago after running the Heart Failure and Transplant program at Johns Hopkins for the prior 15 years. He currently is devoting much of his non-clinical effort to reducing heart failure admissions and readmissions across the Duke Health System hospitals. He is an expert on the treatment of heart failure and has a research interest in exercise physiology in heart failure and left ventricular assist devices.
Nisha A. Gilotra, MD
Director, Heart Failure Bridge Clinic
Assistant Professor of Medicine
Division of Cardiology, Section of Advanced Heart Failure and Transplantation
Johns Hopkins School of Medicine
Baltimore, Maryland
Nisha A. Gilotra, MD, is an Assistant Professor in the Division of Cardiology, Section of Advanced Heart Failure and Transplantation at the Johns Hopkins School of Medicine, where she leads the efforts in Heart Failure Disease Management. Her clinical and academic focus is in heart failure process improvement, including transitions of care. She serves as the Director of the Johns Hopkins Heart Failure Bridge Clinic, a post-hospital disease management program and diuresis clinic that aims to reduce heart failure related hospitalizations. Dr. Gilotra also serves on the Johns Hopkins Heart Failure Quality Improvement Committee and the Johns Hopkins Armstrong Institute for Patient Safety and Quality’s Heart Failure Clinical Community. Additionally, she is the Johns Hopkins principal investigator for several heart failure related clinical trials, and has expertise in cardiac sarcoidosis, myocarditis, heart transplantation and mechanical circulatory support. Dr. Gilotra received her medical degree from Jefferson Medical College in Philadelphia, PA. She completed her medical residency, general cardiology fellowship and advanced heart failure fellowship at Johns Hopkins University School of Medicine.
| 1. | Identify patients with HF who are at greatest risk of health complications and hospitalizations | 2. | Develop a coordinated multidisciplinary plan for interventions that have been shown to be effective in reducing 30-day hospital readmissions in patients with HF |
| 3. | Describe the process to implement interventions for performance improvement in reducing 30-day readmissions in patients with HF | 4. | Evaluate the effectiveness of interventions implemented to reduce 30-day readmissions for patients with HF |
| 1. | Identify patients with HF who are at greatest risk of health complications and hospitalizations |
| 2. | Develop a coordinated multidisciplinary plan for interventions that have been shown to be effective in reducing 30-day hospital readmissions in patients with HF |
| 3. | Describe the process to implement interventions for performance improvement in reducing 30-day readmissions in patients with HF |
| 4. | Evaluate the effectiveness of interventions implemented to reduce 30-day readmissions for patients with HF |
CONTINUING EDUCATION CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement -
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018 – 9999-19-101-H01-P, 0.5 contact hours (0.05 CEU).
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURES
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.
Dr. Russell has nothing to disclose.
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novartis.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
